Get notified when TELA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Dilution of $0.73 Per Share (new) — New investors pay $1.11 per share but receive only $0.38 in net tangible book value, a 66% dilution relative to the offer price.
- No Established Public Trading Market For the Pre-funded Warrants (new) — The pre-funded warrants will not be listed on any exchange, limiting liquidity for investors who receive them.
TELA Bio prices $13.0M offering of 4.19M shares and pre-funded warrants at $1.11
Filed November 14, 2025 · ~2 min read
Key Changes
-
high
TELA Bio is selling 4,189,000 common shares at $1.11 per share, plus pre-funded warrants for up to 7,523,000 shares at $1.1099 each, in a primary offering.
The Offering verify on EDGAR → -
high
Total gross proceeds are approximately $13.0 million; net proceeds to the company are estimated at $11.9 million after underwriting discounts and expenses, assuming no exercise of pre-funded warrants.
Use of Proceeds verify on EDGAR → -
medium
The company intends to use net proceeds for general corporate purposes, including sales and marketing, R&D, general and administrative matters, working capital, and capital expenditures.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (UEC 10-K) is open in full — no account needed.
Partner
Trade TELA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 3, 2026 · How we verify